1. Home
  2. THRD vs CSPI Comparison

THRD vs CSPI Comparison

Compare THRD & CSPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THRD
  • CSPI
  • Stock Information
  • Founded
  • THRD 2019
  • CSPI 1968
  • Country
  • THRD United States
  • CSPI United States
  • Employees
  • THRD N/A
  • CSPI N/A
  • Industry
  • THRD Biotechnology: Pharmaceutical Preparations
  • CSPI EDP Services
  • Sector
  • THRD Health Care
  • CSPI Technology
  • Exchange
  • THRD Nasdaq
  • CSPI Nasdaq
  • Market Cap
  • THRD 157.7M
  • CSPI 146.9M
  • IPO Year
  • THRD 2022
  • CSPI 1987
  • Fundamental
  • Price
  • THRD $3.55
  • CSPI $15.62
  • Analyst Decision
  • THRD Hold
  • CSPI
  • Analyst Count
  • THRD 3
  • CSPI 0
  • Target Price
  • THRD $5.00
  • CSPI N/A
  • AVG Volume (30 Days)
  • THRD 343.0K
  • CSPI 30.9K
  • Earning Date
  • THRD 05-14-2025
  • CSPI 05-07-2025
  • Dividend Yield
  • THRD N/A
  • CSPI 0.77%
  • EPS Growth
  • THRD N/A
  • CSPI N/A
  • EPS
  • THRD N/A
  • CSPI 0.02
  • Revenue
  • THRD N/A
  • CSPI $55,514,000.00
  • Revenue This Year
  • THRD N/A
  • CSPI N/A
  • Revenue Next Year
  • THRD N/A
  • CSPI N/A
  • P/E Ratio
  • THRD N/A
  • CSPI $829.95
  • Revenue Growth
  • THRD N/A
  • CSPI N/A
  • 52 Week Low
  • THRD $3.18
  • CSPI $10.76
  • 52 Week High
  • THRD $16.94
  • CSPI $21.95
  • Technical
  • Relative Strength Index (RSI)
  • THRD 42.90
  • CSPI 44.56
  • Support Level
  • THRD $3.34
  • CSPI $14.80
  • Resistance Level
  • THRD $3.68
  • CSPI $17.94
  • Average True Range (ATR)
  • THRD 0.14
  • CSPI 0.86
  • MACD
  • THRD 0.07
  • CSPI -0.08
  • Stochastic Oscillator
  • THRD 62.86
  • CSPI 26.11

About THRD Third Harmonic Bio Inc.

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

About CSPI CSP Inc.

CSP Inc along with its subsidiaries develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments namely Technology Solutions, where the company focus on value-added reseller integrated solutions including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company design, manufacture and deliver products and services to customers that require specialized cyber security services, networking and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates its maximum revenue from the Americas.

Share on Social Networks: